

****Published February 2017****

MarketVIEW: Herpes simplex virus therapeutic (TX) vaccines (CAT: VAMV038)

| | | |
|-------------------------|---|---|
| Product Name | : | MarketVIEW: Herpes simplex virus therapeutic (TX) vaccines |
| Description | : | Global vaccine commercial opportunity assessment |
| Contents | : | Executive presentation (.pdf) + 1 Excel workbook (.xls) |
| Therapeutic Area | : | Novel adult vaccines |
| Publication date | : | February 2017 |
| Catalogue No | : | VAMV038 |

Background

Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging.

Vaccine manufacturers have pursued the development of both prophylactic (PX) and therapeutic (TX) HSV vaccines albeit with little success to date. For therapeutic approaches a vaccine could reduce the frequency/duration of recurrences and lessen the need for long-term pharmacotherapy. Ideally the vaccine would also reduce transmission (shedding) so having a wider public health benefit. A number of Phase II HSV TX programs operated by Genocea (GEN-003), Agenus (HerpV) and COR-1 (Admedus) have already shown in a clinical setting that a HSV TX vaccine is feasible.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of a HSV therapeutic vaccine across the major Western markets to 2035. The model contains value (\$ m) and volume (mio doses) predictions along with launch timeframe, pricing/penetration estimates and revenues per competitor. LO/BASE/Hi target product profile (TPP) scenarios are included which examine the uptake of vaccines with differing clinical performance. A detailed review is also included on latest trends in disease epidemiology/dynamics and the competitive landscape.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Herpes Simplex Virus (HSV-1/2) epidemiology/vaccines and consulted with global experts regarding their predictions of vaccine deployment. Secondary source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the adolescent field has also been utilised.

PRODUCT CONTENTS:

Published February 2017 (CAT No: VAMV038)

****This product is composed of **one Excel workbook model (.xls)**¹ and **an executive presentation (.pdf)**²

Table of Contents

Executive summary

HSV therapeutic vaccines: Commercial model: key outputs

HSV TX vaccine: total forecast value (\$000s) to 2035

HSV TX vaccine: total forecast volume (000s doses) to 2035

HSV TX vaccine: LOW SCENARIO forecast value (\$000s) to 2035

HSV TX vaccine: BASE SCENARIO forecast value (\$000s) to 2035

HSV TX vaccine: HIGH SCENARIO forecast value (\$000s) to 2035

HSV TX vaccine: forecast value (\$000s) by country/region to 2035

HSV TX vaccine: forecast value (\$000s) by country 5 years post-launch

HSV TX vaccine: volume (000s doses) by country/region to 2035

HSV TX: Genocea (GEN-003) \$ revenues to 2035 (LO/BASE/HI)

HSV TX: Admedus (COR-1) \$ revenues to 2035 (LO/BASE/HI)

HSV TX: VCL-HB01/HM01 \$ revenues to 2035 (LO/BASE/HI)

Calculating TX vaccine target populations to 2035

Herpes simplex virus: Disease background

HSV - the pathogen

Life cycle and pathogenesis of HSV

HSV-1 and HSV-2 life cycles

Clinical manifestations of HSV-1 and HSV-2

Association of HSV-2 and human immunodeficiency virus

Rare, deadly outcomes of HSV infection

Clinical reactivation of HSV-1 and HSV-2

Disease burden and economic burden of HSV

Summary: HSV-1/HSV-2

Herpes simplex virus: Epidemiology

Epidemiology of HSV

Prevalence of HSV-2 infection in 2012 by WHO region

HSV-1/HSV-2 diagnosis

HSV surveillance

Epidemiology: UK

Epidemiology: US

Epidemiology: other markets

¹ Contents available on request

² Presentation titles may apply to more than one slide

Continued.....

- HSV-1 and HSV-2 seroprevalence studies
- HSV-1 as an emerging cause of genital herpes
- Herpes simplex virus: Current management strategies
 - Current management of genital herpes
 - 2016 WHO recommendations for the treatment of genital HSV
 - Novel antivirals in development
- Herpes simplex virus therapeutic vaccines: Rationale for development
 - Evidence that an HSV vaccine is feasible
 - Two approaches to HSV vaccination
 - The role of HSV TX vaccines
 - Questions and considerations on the efficacy of an HSV TX vaccine
 - HSV TX vaccines: past failures
- Herpes simplex virus therapeutic vaccines: Overview of current research and development
 - HSV TX vaccines: overview
 - Overview: HSV TX vaccines in development
 - GEN-003 (Genocea)
 - HerpV (Agenus)
 - COR-1 (Admedus)
 - VCL-HB01/HM01 (Vical)
 - HSV529 (Sanofi)
- HSV therapeutic vaccines: Commercial model assumptions
 - HSV target populations (scenario definition)
 - HSV vaccine: target product profiles
 - Commercial model assumptions: HSV vaccine
 - Markets included in the model
 - Commercial model assumptions
 - HSV vaccine segment analysis
- HSV therapeutic vaccines: Quantifying HSV target populations
 - Calculating TX vaccine target populations
- Bibliography
- About **VacZine Analytics**
- Disclaimer

Slide number = 95

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$10,995**/ GBP **£8,940**# (Region license)*

Indicative company rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



BIBLIOGRAPHY

1. Johnston C, et al. Status of vaccine research and development of vaccines for herpes simplex virus. *Vaccine*. 2016;34:2948-52.
2. Stanfield B & Kousoulas KG. Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections. *Curr Clin Microbiol Rep*. 2015;2:125-36.
3. Looker KH, et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. *PLoS ONE*. 2015;10(10):e0140765.
4. Johnston C & Corey L. Current concepts for genital herpes simplex virus infection: diagnostics and pathogenesis of genital tract shedding. *Clin Microbiol Rev* 2016;29:149-61.
5. Kuo T, et al. The Challenges and Opportunities for Development of a T-Cell Epitope-Based Herpes Simplex Vaccine. *Vaccine*. 2014;32:6733-45.
6. Johnston C, et al. Current status and prospects for development of an HSV vaccine. *Vaccine*. 2014;32:1553-60.
7. Pinninti SG & Kimberlin DW. Preventing HSV in the newborn. *Clin Perinatol*. 2014;41:945-55.
8. Kropp RY, et al. Neonatal herpes simplex virus infections in Canada: results of a 3-year national prospective study. *Pediatrics*. 2006;117:1955-62.
9. Anderson WE. Herpes Simplex Encephalitis. 2016. Available at: <http://emedicine.medscape.com/article/1165183-overview>. Accessed January 2017.
10. Benedetti J, et al. Recurrence rates in genital herpes after symptomatic first-episode infection. *Ann Intern Med*. 1994;121:847-54.
11. Crespi CM, et al. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. *Sex Transm Infect*. 2007;83:359-64.
12. Benedetti JK, et al. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. *Ann Intern Med*. 1999;131:14-20.
13. Engelberg R, et al. Natural history of genital herpes simplex virus type 1 infection. *Sex Transm Dis*. 2003;30:174-7.
14. Vos T, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1603-58.
15. Looker KH, et al. Global Estimates of Prevalent and Incident Herpes Simplex Virus Type 2 Infections in 2012. *PLoS ONE*. 2015;10(1):e114989.
16. Public Health England. Sexually transmitted infections (STIs): annual data tables. 2016. Available at: <https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables>. Accessed January 2017.
17. FPA. Sexually transmitted infections factsheet. 2016. Available at: <http://www.fpa.org.uk/factsheets/sexually-transmitted-infections#references>. Accessed January 2017.
18. Health Protection Agency UK. Current News Infection Reports. Available at: www.hpa.org.uk/hpr/archives/2011/hpr1711.pdf. Accessed January 2017.
19. Morris-Cunnington M, et al. New estimates of herpes simplex virus type 2 seroprevalence in England: 'high' but stable seroprevalence over the last decade. *Sex Transm Dis*. 2004;31:243-6.
20. Centers for Disease Control and Prevention (CDC). Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. *MMWR Morb Mortal Wkly Rep*. 2010;59:456-9.
21. Xu F, et al. Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States. *JAMA*. 2006;296:964-973.
22. Xu F, et al. Seroprevalence of herpes simplex virus type 1 in children in the United States. *J Pediatr*. 2007;151:374-7.
23. Schulte JM, et al. HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women). *South Med J* 2014;107:79-84.
24. CDC. 2015 Sexually Transmitted Diseases Surveillance. 2015. Available at: <https://www.cdc.gov/std/stats15/default.htm>. Accessed January 2017.
25. Brackbill RM, et al. Where do people go for treatment of sexually transmitted diseases? *Fam Plann Perspect*. 1999;31:10-5.
26. Malkin JE, et al. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. *Sex Transm Infect*. 2002;78:201-203.
27. Sauerbrei A, et al. Seroprevalence of herpes simplex virus type 1 and type 2 in Thuringia, Germany, 1999 to 2006. *Euro Surveill*. 2013;16:pii: 20005.
28. Howard M, et al. Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada. *J Clin Microbiol* 2003;41:84-9.

29. Cunningham AL, et al. Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey. *Sex Transm Infect.* 2006;82:164-8.
30. Doi Y, et al. Seroprevalence of herpes simplex virus 1 and 2 in a population-based cohort in Japan. *J Epidemiol.* 2009;19:56-62.
31. Suligoï B, et al. HSV-2 specific seroprevalence among various populations in Rome, Italy. *The Italian Herpes Management Forum. Sex Transm Infect.* 2000;76:213-4.
32. Garcia-Corbeira P, et al. Is sexual transmission an important pattern for herpes simplex type 2 virus seroconversion in the Spanish general population? *J Med Virol* 1999;59:194-7.
33. Gorfinkel IS, et al. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial. *Int J STD & AIDS.* 2013;24:345-9.
34. Malvy D et al. Epidemiology of genital herpes simplex virus infections in a community-based sample in France: results of the HERPIMAX study. *Sex Transm Dis.* 2005;32(8):499-505.
35. Ryder N, et al. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. *Sex Transm Infect.* 2009;85:416-9.
36. Gilbert M, et al. Using centralized laboratory data to monitor trends in herpes simplex virus type 1 and 2 infection in British Columbia and the changing etiology of genital herpes. *Can J Public Health.* 2011;102:225-9.
37. Janier M, et al. Virological, serological and epidemiological study of 255 consecutive cases of genital herpes in a sexually transmitted disease clinic of Paris (France): a prospective study. *Int J STD AIDS.* 2006;17:44-9.
38. Solomon L, et al. Epidemiology of recurrent genital herpes simplex virus types 1 and 2. *Sex Transm Infect.* 2003;79:456-9.
39. WHO. Guidelines for the treatment of genital herpes simplex virus. 2016. ISBN-13: 978-92-4-154987-5. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK396232/>. Accessed January 2017.
40. Schwartz EJ, et al. Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines. *Hum Vaccin.* 2007;3:231-8.
41. Straus SE, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. *J Infect Dis.* 1997;176:1129-34.
42. Casanova G, et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. *Cutis.* 2002;70:235-9.
43. Wald A, et al. Novel Therapeutic Vaccine for Genital Herpes Reduces Genital HSV-2 Shedding. *ICAAC 2013;Abstract G-1458a.*
44. Flechtner JB, et al. Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial. *Vaccine.* 2016;34:5314-20.
45. Fife K, et al. GEN-003, a Therapeutic Vaccine for Genital Herpes, Significantly Reduces Viral Shedding and Lesions for at Least 6 Months. *ASM Microbe 2016;Abstract PW-039.*
46. Genocea. GEN-003 for Genital Herpes. 2016. Available at: <http://www.genocea.com/pipeline/gen003-for-genital-herpes/>. Accessed January 2017.
47. Genocea. Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial. 2017. Available at: <http://ir.genocea.com/releases.cfm/>. Accessed January 2017.
48. Wald A, et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. *Vaccine.* 2011;29:8520-9.
49. Agenus. Agenus' HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial. 2014. Available at: <http://investor.agenusbio.com/2013-11-07-Agenus-HerpV-Therapeutic-Vaccine-for-Genital-Herpes-Meets-Primary-Endpoint-in-Randomized-Phase-2-Trial>. Accessed January 2017.
50. Agenus. Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation. 2014. Available at: <http://investor.agenusbio.com/2014-06-26-Agenus-Vaccine-Shows-Significant-Reduction-in-Viral-Burden-after-HerpV-Generated-Immune-Activation?printable>. Accessed January 2017.
51. FiercePharma. UPDATED: Analyst: Genocea's genital herpes vaccine better positioned than Agenus' to enter market. 2015. Available at: <http://www.fiercepharma.com/infectious-diseases/updated-analyst-genoeceas-genital-herpes-vaccine-better-positioned-than-agenus>. Accessed January 2017.
52. Drug Discovery & Development. HerpV, GEN-003 Will Drive Genital Herpes Treatment Market Growth to 2023. 2015. Available at: <http://www.dddmag.com/article/2015/07/herpv-gen-003-will-drive-genital-herpes-treatment-market-growth-2023>. Accessed January 2017.
53. Admedus. Immunotherapies. 2016. Available at: <http://www.admedus.com/au/technology/immunotherapies/>. Accessed January 2017.

54. Admedus. ADMEDUS ANNOUNCES POSITIVE UNBLINDED HSV-2 PHASE II INTERIM DATA. 2016. Available at: <http://clients2.weblink.com.au/clients/admedus/article.asp?asx=AHZ&view=6794860>. Accessed January 2017.
55. Veselenak RL, et al. A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. *Vaccine*. 2012;30:7046-51.
56. Vical. HSV-2 therapeutic vaccine. 2016. Available at: <http://www.vical.com/products/HSV-2-vaccine/default.aspx>. Accessed January 2017.
57. Bernard MC, et al. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs. *PLoS One*. 2015;10(4):e0121518.
58. Sanofi Pasteur. Sanofi Pasteur and Immune Design Collaborate on a Vaccine to Treat Herpes Simplex Virus. 2014. Available at: <http://www.sanofipasteur.com/en/articles/sanofi-pasteur-and-immune-design-collaborate-on-a-vaccine-to-treat-herpes-simplex-virus.aspx>. Accessed January 2017.
59. Johnston C, et al. HSV-2: in pursuit of a vaccine. *J Clin Invest*. 2011;121:4600-9.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 813155
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009